ReviewUrologic oncology2013
The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies.
Review in Urologic oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- Adverse histological features are more commonly observed in hypergonadotropic prostate cancer patients.The Canadian journal of urology · 2025Article
- Extra-Gonadal and Non-Canonical Effects of FSH in Males.Pharmaceuticals (Basel, Switzerland) · 2023Review
- A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [Molecules (Basel, Switzerland) · 2019Review
- Small Molecule Follicle-Stimulating Hormone Receptor Agonists and Antagonists.Frontiers in endocrinology · 2018Review
- Simultaneous Measurements of Follicle Stimulating Hormone and Total Testosterone and Associations in Clinically Localized Prostate Cancer.Current urology · 2017Article
- Parity History Determines a Systemic Inflammatory Response to Spread of Ovarian Cancer in Naturally Aged Mice.Aging and disease · 2017Article
- In vivo targeting of metastatic breast cancer via tumor vasculature-specific nano-graphene oxide.Biomaterials · 2016Article
- An Investigation on a Novel Anti-tumor Fusion Peptide of FSH33-53-IIKK.Journal of Cancer · 2016Article
- Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer.Cancer immunology research · 2015Article
- PET of follicle-stimulating hormone receptor: broad applicability to cancer imaging.Molecular pharmaceutics · 2015Article
- Structure-function relationships of glycoprotein hormones and their subunits' ancestors.Frontiers in endocrinology · 2015Review
- Pilot study of a novel (18)F-labeled FSHR probe for tumor imaging.Molecular imaging and biology · 2014Article
- Experience with degarelix in the treatment of prostate cancer.Therapeutic advances in urology · 2013Article
- Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du CanadaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Follicle-stimulating hormone (FSH) is a central hormone in mammalian reproductive biology. The FSH receptor (FSHR), which was previously believed to be expressed primarily in the ovary and testis, was recently found to be expressed in the tumor blood vessels of many solid tumor types, including prostate adenocarcinoma, urothelial carcinoma, and renal cell carcinoma. While the biologic significance of FSHR in tumor blood vessels has yet to be elucidated, FSHR may contribute to neoangiogenesis. FSHR has been reported to be expressed by prostate cancer cells and, thus, targeting FSHR in prostate cancer may be of particular utility. In this report, we discuss the finding of FSHR in tumor blood vessels and review the literature concerning FSHR in genitourinary malignancy. We also discuss the features that make FSHR an appealing target for therapeutic and imaging purposes and the potential utility of FSHR as a prognostic and/or predictive biomarker in genitourinary cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.